News Sentiment

EYPT sentiment intelligence

Eyepoint Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 14.72 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+5.3% over one week, +13.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Two New EyePoint Employees Receive Options for 63,500 Shares

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 5.3% Price confirming higher
Trend fit Trend inactive 13.0% over four weeks
Fair value 19.9% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 34
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
Stock Titan 6
simplywall.st 6
Investing.com 5
TradingKey 5
GlobeNewswire 3
Ophthalmology Times Europe 3
TradingView 3

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 12
Analyst action 6
Regulatory and legal 2
Guidance 1
Balance sheet 1
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Stock Titan Direct company coverage

Two New EyePoint Employees Receive Options for 63,500 Shares

EyePoint (Nasdaq: EYPT) granted non-statutory stock options for up to 63,500 common shares to two new employees on July 15, 2026, as inducement awards under NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $13.85, a ten-year term, and vest over four years, su

Tone
Positive 61/100
Event
Market update
Published
16 Jul 2026 11:11
Source
Stock Titan
GlobeNewswire Direct company coverage

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint, Inc. (Nasdaq: EYPT) announced inducement grants of non-statutory stock options to two new employees. These grants, totaling 63,500 shares of common stock, were made outside the company’s 2023 Long-Term Incentive Plan under NASDAQ Listing Rule 5635(c)(4) to incentivize t

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 11:11
Source
GlobeNewswire
Investing.com Direct company coverage

Stifel initiates EyePoint stock with buy rating on retinal drug potential

Stifel has initiated coverage on EyePoint Inc. with a buy rating and a $40.00 price target, citing the potential of its sustained-delivery retinal disease treatment, Duravyu. The drug is expected to offer extended treatment intervals for patients with retinal diseases and its piv

Tone
Positive 70/100
Event
Analyst action
Published
16 Jul 2026 04:54
Source
Investing.com
GlobeNewswire Direct company coverage

EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer

EyePoint, Inc. appointed Tarek S. Hassan, M.D., a globally renowned retina specialist, as their Chief Strategic Science Officer. Dr. Hassan will provide strategic guidance for the company's clinical development, commercialization, and pipeline initiatives, particularly for their

Tone
Positive 75/100
Event
Guidance
Published
14 Jul 2026 04:42
Source
GlobeNewswire
VisionMonday.com Direct company coverage

EyePoint Names Tarek S. Hassan, MD, as SVP and Chief Strategic Science Officer

EyePoint, Inc. has appointed Tarek S. Hassan, MD, as Senior Vice President and Chief Strategic Science Officer. Dr. Hassan, a renowned retina specialist with 35 years of experience, will guide the company's portfolio development, focusing on pipeline assets like Duravyu for serio

Tone
Positive 70/100
Event
Market update
Published
14 Jul 2026 00:24
Source
VisionMonday.com
Simply Wall Street Direct company coverage

Does EyePoint’s (EYPT) Broad Russell Index Debut Quietly Recast Its DURAVYU‑Centric Investor Base?

EyePoint (EYPT) was recently added to several Russell growth and small-cap indices, increasing its visibility to index-tracking investors. While this broadens exposure, the company's investment narrative still heavily relies on the success of its single asset, DURAVYU, with criti

Tone
Positive 65/100
Event
Market update
Published
10 Jul 2026 16:10
Source
Simply Wall Street
Ad Hoc News Direct company coverage

EyePoint Pharmaceuticals updates its strategy as retinal pipeline advances

EyePoint Pharmaceuticals is updating its strategy as its pipeline of long-acting eye therapies for retinal diseases advances. The company specializes in sustained intraocular drug delivery, aiming to reduce treatment burden for patients. Its focus is on developing proprietary imp

Tone
Positive 71/100
Event
Market update
Published
09 Jul 2026 03:09
Source
Ad Hoc News
Stock Traders Daily Direct company coverage

Price-Driven Insight from (EYPT) for Rule-Based Strategy

This article provides a price-driven analysis for Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT), indicating a near-term neutral sentiment amidst mid and long-term strength. It outlines various AI-generated trading strategies including position, momentum breakout, and risk hedging,

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 06:38
Source
Stock Traders Daily
Ophthalmology Times Europe Direct company coverage

EyePoint shared additions to scientific advisory board and conditional approval of trade name for EYP-1901

EyePoint Pharmaceuticals has expanded its Scientific Advisory Board by appointing three leading ophthalmologists: Usha Chakravarthy, Allen Ho, and Frank Holz. These additions will support the company's global clinical strategy as it prepares for Phase 3 trials for wet age-related

Tone
Positive 71/100
Event
Regulatory and legal
Published
07 Jul 2026 03:10
Source
Ophthalmology Times Europe
Investing.com Direct company coverage

Guggenheim reiterates Buy on EyePoint stock, cites trial progress

Guggenheim has reiterated a Buy rating on EyePoint Inc. (NASDAQ:EYPT) with a $68.00 price target, citing promising progress in the company's clinical trials for wet age-related macular degeneration and diabetic macular edema. Enrollment is complete for the LUGANO and LUCIA trials

Tone
Positive 71/100
Event
Analyst action
Published
06 Jul 2026 02:10
Source
Investing.com
Ad-hoc-news.de Direct company coverage

EyePoint Pharmaceuticals outlines long-term retina strategy as a specialty biotech

EyePoint Pharmaceuticals is a specialty biopharmaceutical company focused on developing sustained drug delivery technologies for serious retinal diseases. The company aims to address the burden of frequent treatments for conditions like age-related macular degeneration by providi

Tone
Positive 74/100
Event
Market update
Published
03 Jul 2026 19:09
Source
Ad-hoc-news.de
Investing.com Canada Direct company coverage

Form 4 Eyepoint Pharmaceuticals Inc For: 2 July By Investing.com

This article reports on a Form 4 filing for Eyepoint Pharmaceuticals Inc. for transactions that occurred on July 2nd. It is a brief announcement from Investing.com and does not contain further details within the main body. The article is surrounded by various financial market dat

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:42
Source
Investing.com Canada
Investing.com Direct company coverage

EyePoint CMO Ramiro Ribeiro sells $73,166 in company stock

EyePoint, Inc.'s Chief Medical Officer, Ramiro Ribeiro, recently sold 4,875 shares of company stock, totaling approximately $73,166, after exercising stock options. Following these transactions, Ribeiro holds no direct shares but retains 153,564 stock options. The company is repo

Tone
Negative 38/100
Event
Market update
Published
02 Jul 2026 20:40
Source
Investing.com
Investing.com Canada Direct company coverage

EyePoint CMO Ramiro Ribeiro sells $73,166 in company stock By Investing.com

EyePoint's Chief Medical Officer, Ramiro Ribeiro, sold $73,166 worth of company stock after exercising options. These transactions, occurring on June 30, 2026, leave Ribeiro with no direct shares but 153,564 stock options. Despite the sale, the stock currently trades below the sa

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:42
Source
Investing.com Canada
www.marketscreener.com Direct company coverage

EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 2500 Growth Benchmark

EyePoint, Inc. (NasdaqGM: EYPT), a clinical-stage biopharmaceutical company focusing on treatments for serious retinal diseases, has been added to the Russell 2500 Growth Benchmark. The company's lead product candidate, DURAVYU, is currently in Phase III pivotal trials for wet ag

Tone
Positive 75/100
Event
Market update
Published
29 Jun 2026 19:11
Source
www.marketscreener.com
marketscreener.com Direct company coverage

EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 2000 Growth Benchmark

EyePoint, Inc. (NasdaqGM: EYPT) has been added to the Russell 2000 Growth Benchmark. The company, a clinical-stage biopharmaceutical firm, is focused on developing therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU, currently undergoing Phase III

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 10:37
Source
marketscreener.com
TradingView Direct company coverage

EYPT Forecast — Price Target — Prediction for 2027

This article provides an overview of EyePoint, Inc. (EYPT) stock performance and analyst forecasts. It includes the current stock price, historical highs and lows, market capitalization, volatility, and details on recent earnings and revenue. Analysts have provided target prices

Tone
Positive 64/100
Event
Earnings
Published
27 Jun 2026 11:39
Source
TradingView
Investing.com Direct company coverage

Mizuho reiterates EyePoint stock rating on competitor timeline shift

Mizuho has reiterated an Outperform rating and $36.00 price target for EyePoint Inc. following news that a competitor, Ocular Therapeutix, has delayed its NDA submission timelines for a rival product. This development is seen as positive for EyePoint, which expects top-line resul

Tone
Positive 70/100
Event
Analyst action
Published
23 Jun 2026 12:12
Source
Investing.com